​

Verrica Pharmaceuticals (VRCA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

VRCA Stock Forecast

Verrica Pharmaceuticals (VRCA) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $12.00, with a high of $14.00 and a low of $10.00. This represents a 2400.00% increase from the last price of $0.48.

- $3 $6 $9 $12 $15 High: $14 Avg: $12 Low: $10 Last Closed Price: $0.48

VRCA Stock Rating

Verrica Pharmaceuticals stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (50.00%), 5 Hold (50.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 5 5 Strong Sell Sell Hold Buy Strong Buy

VRCA Price Target Upside V Benchmarks

TypeNameUpside
StockVerrica Pharmaceuticals2400.00%
SectorHealthcare Stocks 33.91%
IndustryBiotech Stocks 83.49%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$13.00
Last Closing Price$0.48$0.48$0.48
Upside/Downside--2608.33%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25-24--6
Mar, 25-24--6
Feb, 25-24--6
Jan, 25-24--6
Dec, 24-24--6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 14, 2024Glen SantangeloJefferies$12.00$11.286.38%2400.00%
May 14, 2024Oren LivnatH.C. Wainwright$14.00$9.5646.44%2816.67%
Jul 25, 2023Serge BelangerNeedham$10.00$5.3287.97%1983.33%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 21, 2024Cowen & Co.BuyBuyhold
Oct 02, 2024NeedhamBuyHolddowngrade
May 14, 2024JefferiesBuyBuyhold
May 14, 2024H.C. WainwrightBuyBuyhold
Jul 25, 2023NeedhamBuyupgrade
Feb 13, 2023RBC CapitalSector PerformOutperformupgrade
May 25, 2022RBC CapitalSector Performdowngrade

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.44$-0.81$-1.48$-1.48----
Avg Forecast$-1.46$-0.91$-1.39$-1.45$-0.60$-0.37$-0.13$-0.01
High Forecast$-0.99$-0.71$-1.34$-1.34$-0.24$-0.10$0.17-
Low Forecast$-1.87$-1.25$-1.44$-1.55$-0.79$-0.66$-0.62$-0.01
Surprise %-1.37%-10.99%6.47%2.07%----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$12.00M$9.03M$5.12M$7.57M----
Avg Forecast$12.00M$7.42M$4.03M$8.25M$14.34M$32.60M$65.81M$101.80M
High Forecast$14.60M$9.53M$4.33M$9.44M$14.68M$44.27M$89.36M$138.24M
Low Forecast$9.06M$6.15M$3.87M$7.07M$14.01M$22.30M$45.02M$69.64M
Surprise %-21.80%27.29%-8.34%----

Net Income Forecast

$-85M $-66M $-47M $-28M $-9M $10M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-38.90M$-27.68M$-67.00M$-76.58M----
Avg Forecast$-65.97M$-41.45M$-63.07M$-65.34M$-23.53M$-17.19M$846.33K$-226.71K
High Forecast$-44.98M$-32.26M$-60.85M$-60.63M$-11.03M$-4.67M$7.64M$-133.60K
Low Forecast$-84.58M$-56.82M$-65.28M$-70.06M$-36.03M$-29.71M$-28.13M$-332.19K
Surprise %-41.03%-33.23%6.23%17.20%----

VRCA Forecast FAQ

Is Verrica Pharmaceuticals stock a buy?

Verrica Pharmaceuticals stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Verrica Pharmaceuticals is a favorable investment for most analysts.

What is Verrica Pharmaceuticals's price target?

Verrica Pharmaceuticals's price target, set by 10 Wall Street analysts, averages $12 over the next 12 months. The price target range spans from $10 at the low end to $14 at the high end, suggesting a potential 2400.00% change from the previous closing price of $0.48.

How does Verrica Pharmaceuticals stock forecast compare to its benchmarks?

Verrica Pharmaceuticals's stock forecast shows a 2400.00% upside, outperforming the average forecast for the healthcare stocks sector (33.91%) and outperforming the biotech stocks industry (83.49%).

What is the breakdown of analyst ratings for Verrica Pharmaceuticals over the past three months?

  • April 2025: 0% Strong Buy, 33.33% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 0% Strong Buy, 33.33% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 0% Strong Buy, 33.33% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.

What is Verrica Pharmaceuticals’s EPS forecast?

Verrica Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.6, marking a -59.46% decrease from the reported $-1.48 in 2024. Estimates for the following years are $-0.37 in 2026, $-0.13 in 2027, and $-0.01 in 2028.

What is Verrica Pharmaceuticals’s revenue forecast?

Verrica Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $14.34M, reflecting a 89.59% increase from the reported $7.57M in 2024. The forecast for 2026 is $32.6M, followed by $65.81M for 2027, and $101.8M for 2028.

What is Verrica Pharmaceuticals’s net income forecast?

Verrica Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-23.529M, representing a -69.28% decrease from the reported $-76.579M in 2024. Projections indicate $-17.187M in 2026, $846.33K in 2027, and $-227K in 2028.